Adding a neutralizing IFNγ antibody to anti-PD-L1/TGFβ treatment completely inhibited the anti-tumor response caused by the combination, demonstrating the IFNγ dependency of the dual blockade (Fig. 6g). This evidence concerns the gene TGFB1 and neoplasm.